← Back to patent-cliff list
BR-2251
Tier C — Watch / tradeBR-2251
Shanton Pharma Pte Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：URAT1
Indications (approved)：Hyperuricaemia, Gout
Regional status
US
Phase II
2019-01-01
EU
-
China
Phase II
2026-04-01
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of BR-2251?
Approved indications include: Hyperuricaemia, Gout.
When does the BR-2251 patent expire?
No public expiry year is available for BR-2251 yet; this page updates once verified.
How do I get a quote for BR-2251 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-08